614 related articles for article (PubMed ID: 37626604)
1. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
Staufer K; Stauber RE
Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
[TBL] [Abstract][Full Text] [Related]
2. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
Ochoa-Allemant P; Marrero JA; Serper M
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
[TBL] [Abstract][Full Text] [Related]
3. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
[TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
Moon JH; Jeong S; Jang H; Koo BK; Kim W
EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
[TBL] [Abstract][Full Text] [Related]
7. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
8. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
[TBL] [Abstract][Full Text] [Related]
9. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
Lee BP; Dodge JL; Terrault NA
Hepatology; 2024 Mar; 79(3):666-673. PubMed ID: 37732946
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study.
Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Fukao T; Shimizu M; Yamamoto M
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398471
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
Kalligeros M; Vassilopoulos A; Vassilopoulos S; Victor DW; Mylonakis E; Noureddin M
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1330-1332.e4. PubMed ID: 37949334
[TBL] [Abstract][Full Text] [Related]
12. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
Loomba R; Wong VW
Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
[TBL] [Abstract][Full Text] [Related]
13. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
[TBL] [Abstract][Full Text] [Related]
14. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.
Kim GA; Moon JH; Kim W
Clin Mol Hepatol; 2023 Oct; 29(4):831-843. PubMed ID: 37634892
[TBL] [Abstract][Full Text] [Related]
15. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
16. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN;
J Hepatol; 2023 Dec; 79(6):1542-1556. PubMed ID: 37364790
[TBL] [Abstract][Full Text] [Related]
17. Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis.
Nasr P; Wester A; Ekstedt M; Strandberg R; Kechagias S; Shang Y; Widman L; Hagström H
Clin Gastroenterol Hepatol; 2024 May; 22(5):1048-1057.e2. PubMed ID: 38237695
[TBL] [Abstract][Full Text] [Related]
18. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
[TBL] [Abstract][Full Text] [Related]
19. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
Younossi ZM; Alqahtani SA; Alswat K; Yilmaz Y; Keklikkiran C; Funuyet-Salas J; Romero-Gómez M; Fan JG; Zheng MH; El-Kassas M; Castera L; Liu CJ; Wai-Sun Wong V; Zelber-Sagi S; Allen AM; Lam B; Treeprasertsuk S; Hameed S; Takahashi H; Kawaguchi T; Schattenberg JM; Duseja A; Newsome PN; Francque S; Spearman CW; Castellanos Fernández MI; Burra P; Roberts SK; Chan WK; Arrese M; Silva M; Rinella M; Singal AK; Gordon S; Fuchs M; Alkhouri N; Cusi K; Loomba R; Ranagan J; Eskridge W; Kautz A; Ong JP; Kugelmas M; Eguchi Y; Diago M; Yu ML; Gerber L; Fornaresio L; Nader F; Henry L; Racila A; Golabi P; Stepanova M; Carrieri P; Lazarus JV;
J Hepatol; 2024 Mar; 80(3):419-430. PubMed ID: 37984709
[TBL] [Abstract][Full Text] [Related]
20. [Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases].
Chen L; Jiang LN; Zhao JM
Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):805-809. PubMed ID: 37723061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
